Patients with chronic obstructive pulmonary disease (COPD) have multiple breathing problems and, at the more severe stages, experience acute exacerbations of COPD up to three times annually. Because ...

Bronchodilators are the cornerstone of pharmacological management of chronic obstructive pulmonary disease (COPD), and current guidelines recommend their use as first-line therapy in symptomatic ...

GlaxoSmithKline's experimental once-daily lung drug LAMA/LABA showed positive results on Monday from late stage trials in patients with chronic obstructive pulmonary disease (COPD). The Phase III data ...

SAN DIEGO — Patients who received a free or fixed-dose combination of a long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) experienced a lower risk for chronic obstructive ...

LA JOLLA, Calif., July 30, 2025--(BUSINESS WIRE)--AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory ...

April 14, 2020--Clinicians grappling with the pharmacologic management of COPD in patients complaining of exercise intolerance or dyspnea now have new guidance. The American Thoracic Society has ...

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...

Using a LABA in combination with a LAMA rather than an inhaled corticosteroid to treat COPD is more effective in preventing exacerbations, claim researchers. Patients receiving a combination of ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

LONDON and SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 12/18/12 -- GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application in the US for ...

Changing patients from an inhaled corticosteroid (ICS)/long-acting β agonist (LABA) inhaler and long-acting muscarinic agonist (LAMA) inhaler to a LAMA/LABA inhaler and a separate ICS inhaler did not ...

GlaxoSmithKline has completed final stage testing of its experimental once-daily lung disease drug LAMA/LABA and will press ahead with plans to file for approval of the medicine in global markets from ...